Τόμος 5 (1991) – Τεύχος 1 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 5 (1991) – Issue 1 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. PHARMAKON-Press Information Services, Athens, Greece

2. Laboratory of Drug Metabolism, Department of Pharmacology, Geneva, Switzerland

3. Laboratory of Experimental Surgery and Surgical Research, University of Athens, School of Medicine, Athens, Greece

Accepted for publication: January 25, 1991

pharmakonpress[at]pharmakonpress[.]gr

2.       Sjöqvist, F.: Polymorphic drug oxidation: Implications for therapeutic drug monitoring. In: European Consensus Conference on Pharmacogenetics (G. Alvan et al., eds), p. 97, CEE, Brussels – Luxembourg, 1990

3.       Vogel, F.: Moderne Probleme der Humangenetik. Ergehn. Inn. Med. Kinderhellkd. 12: 52 (1959)

4.       Plessas, C.T., Plessas, S.T.: Introduction to Pharmaco-genetics. Pharmacochemicaf No 133: 50 (1981)

5.       Benakis, A.: Genetics polymorphisms and their revelance for drug development. Epitheor. Klin. Farmakol. Farma- kokinet. El. Ekd. 8: 180 (1990)

6.       F. Vogel, A.G. Motulski (eds): Human Genetic. Springer Verlag, Berlin, 1979

7.       McQueen, E.G.: Pharmacological basis of adverse drug reactions. In: Avery’s Drug Treatment (T.M. Speight, ed.), p. 239, ADIS Press, Auckland, Sydney, 1987

8.       Evans, D.A.P., Manley, K.A., McKusick, V.A.: Genetic control of isoniazid metabolism in man. Br. Med. J. 2: 485 (1960)

9.       Meyer, U.A., Zanger, U.M., Skoda, R.C., Grant, D., Blum, M.: Genetic polymorphisms of drug metabolism. Progr. Liver. Dis. 9: 307 (1990)

10.     W. Kalow, H.W., Goedde, D.P. Agarwal (eds): Ethnic Differences in Reactions to Drugs and Xenobiotics. Alan R. Liss, New York, 1986

11.     Bertilsson, L.: Interethnic differences in drug oxidation polymorphism. In: See Ref. 2, p. 171, C.E.E., 1990

12.     Meyer, U.A.: Genetic polymorphisms of drug metabolizing enzymes: Molecular mechanisms. In: See Ref. 2, p. 7, C.E.E., 1990

13.     Clark, D.W.J.: Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29: 342 (1985)

14.     Weber, W.W., Hein, D.W.: N-acetylation pharmacogenetics. Pharmacol. Rev. 37: 25 (1985)

15.     Evans, D.A.P.: N-acetyltransferase. Pharmacol. Ther. 42: 157 (1989)

16.     Rao, K.V.N., Mitchison, D.A., Nair, N.G.K., Prema, Κ., Tripathy, S.P.: Sulphadimidine acetylation test for classification of patients as slow or rapid acetylators of isoniazid. Br. Med. J. 3: 495 (1970)

17.     Carr, Κ., Oates, J.A., Nies, A.S., Woolsey, R.L: Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br. J. Clin. Pharmacol. 6: 421 (1978)

18.     Reidenberg, M.M., Drayer, D.E., Levy, M., Warner, H.: Polymorphic acétylation of procainamide in man. Clin. Pharmacol. Ther. 17: 722 (1975)

19.     Grant, D.M., Tang, B.K., Kalow, W.: A simple test for acetylator phenotype using caffeine. Br. J. CUn. Pharmacol. 17: 459 (1984)

19a. Plessas, C.T., Plessas, S.T.: Biological effects of caffeine. Epitheor. Klin. Farmakol. Farmakokinet. EL Ekd. 3: 1 (1985)

20.     Gascon, M.P., Leeman, T., Dayer, P.: Evaluation d’un test à la cafeine pour déterminer le phénotype de la N-acétyltransférase (NAT). Schweiz. Med. Wschr. 117: 1974 (1987)

21.     Bechtel, Y.C., Joanne, C., Grandmottet, M., Bechtel, P.R.: The influence of insulin dependent diabetes on the metabolism of caffeine and the expression of the debrisoquin oxidation phenotype. Clin. Pharmacol. Ther. 44: 408 (1988)

22.     Bechtel, P.R., Bechtel, Y.: N-Acetyl transferase. In: See ref. 2, p. 161, C.E.E., 1990 23.     Tang, B.K., Kadar, D.M., Kalow, W.: An alternative test for acetylator phenotyping with caffeine, Clin. Pharmacol. Ther. 42: 509 (1987)

24.     Reidenberg, M.M.: Potential artifacts in the use of caffeine to determine acétylation phenotype. Br. J. Clin. Pharmacol. 28: 207 (1989)

25.     du Souich, P., Laika, D., Slaughter, R., Elvin, A.T., McLean, A.J.: Mechanisms of non-linear disposition kinetics of sulphamethazine. CUn. Pharmacol. Ther. 25: 757 (1979)

26.     Ahmad, R.A., Rogers, H.J., Vandenburg, M., Wright, P.: Effects of concurrent administration of other substances of N-acetyltransferase on dapsone acétylation. Br. J. Clin. Pharmacol. 12: 83 (1981)

27.     Raghupati Sarma, G., Kailasam, S., Nair, N.G.K., Narayana, S.L., Tripathy, S.P.: Effect of prednisolone and rifampicin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob. Agents Chemother. 18: 661 (1980)

28.     Olsen, H., Morland, J.: Ethanol-induced increase in drug acétylation in man and isolated rat cells. Br. Med. J. 2: 1260 (1978)

29.     Levi, A.J., Sherlock, S., Walker, D.: Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1: 1275 (1968)

30.     Fine, A., Sumner, D.J.: Determination of acetylator status in uraemia. Br. J. Clin. Pharmacol. 2: 475 (1975)

31.     Bulovskaya, L.N., Krupkin, R.G., Bochina, T.A., Shipkova, A.A., Pavlova, M.V.: Acetylator phenotype in patients with breast cancer. Oncology 35: 185 (1978)

32.     Chapron, D.J., Kramer, P.A., Mercik, S.A.: Potential influence of body weight on the clearance of polymorphically acetyl a ted drugs. J. Clin. Pharmacol. 22: 271 (1982)

33.     Grant, D.M., Mörike, K., Eichelbaum, M., Meyer, U.A.: Acétylation pharmacogenetis. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J. Clin. Invest. 85: 968 (1990)

34.     Weber, W.W., Cohen, S.N., Steinberg, M.S.: Purification and properties of N-acetyltransferase from mammalian liver. Ann. N.Y. Acad. Sci. 151: 734 (1968)

35.     Grant, D.M., Lottspeich, F., Meyer, U.A.: Evidence for two closely related isozymes of arylamine N-acetyl-transferase in human liver. FEBS Lett. 244: 203 (1989)

36.     Brosen, Κ.: Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Cfin. Pharmacokinet. 18: 220 (1990)

37.     Mahgoub, A., Idle, J.R., Lancaster, R., Smith, R.L.: Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584 (1977)

38.     Eichelbaum, M., Spannbucker, N„ Dengler, H.J.: Influence of the defective metabolism of sparteine on its pharmacokinetics. Ear. J. Clin. Pharmacol. 16: 189 (1979)

39.     Cipfer, A., Preisig, R.: Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26: 753 (1984) 40.     Tang, B.K., Kolow, W., Inaba, T. et al.: Variation in amobarbital metabolism: evaluation of a simplified population study. Clin. Pharmacol. Ther. 34: 202 (1983)

41.     Nebert, D.W., Adesnik, M., Coon, M.J. et al.: The P450 gene superfamily: Recommended nomenclature. DNA 6: 1 (1987)

42.     Nebert, D.W., Nelson, D.R., Adesnik, M., Coon, M.J., Estabrook, R.W., Gonzalez, F.J., Guengerich, F.P., Gunsalus, I.C., Johnson, E.F., Kemper, B., Levin, W., Phillips, I.R., Sato, R., Waterman, M.R.: The P450 gene superfamily: Update fisting of all genes and recommended nomenclature of chromosomal loci. DNA 8: 1 (1989)

43.     Gonzalez, F.: The molecular biology of cytochrome P450s. Pharmacol. Rev. 40: 243 (1989)

44.     Nelson, D.R., Strobel, H.W.: Evolution of P450 proteins. Mot. Biol. Evol. 4: 572 (1987)

45.     Idle, J.R., Mahgoub, A., Angelo, M.M. et al.: The metabolism of (MC) debrisoquine in man. Br. J. Clin. Pharmacol. 7: 257 (1979)

46.     Eichelbaum, M., Bertilsson, L., Sawe, J., Zekorn, C.: Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin. Pharmacol. Ther. 31: 184 (1982)

47.     Jacqz, E., Hall, S.D., Branch, R.A.: Genetically determined polymorphisms in drug oxidation. Hepatology 6: 1020 (1986)

48.     Steiner, E., Iselins, L, Alvan, G., Linsten, J., Sjöqvist, F.: A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin. Pharmacol. Ther. 389: 394 (1985)

49.     Eichelbaum, M., Reetz, Κ.-P., Schmidt, E.K., Zekorn, C.: The genetic polymorphism of sparteine polymorphism. Xenobiotica 16: 465 (1986)

50.     Bertilsson, L.: Interethnic differences in drug oxidation polymorphism. In: See ref. 2, p. 171, C.E.E., 1990

51.     Dayer, P.: Advantages and drawbacks of probe drugs for the assessment of phenotyping expression of cytochrome P450db1 (P450IID6). In: See ref. 2, p. 33, C.E.E., 1990

52.     Kallio, J., Lindberg, R., Huupponen, R., lisalo, E.: Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Br. J. C/in. Pharmacol. 26: 791 (1988)

53.     Syvälathi, E.K.G., Lindberg, R., Kallio, J., De Vocht, M.: Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br. J. Clin. Pharmacol. 22: 89 (1986)

54.     Ayesh, R„ Scadding, J., Brostoff, J., Idle, J.R., Smith, R.L.: Stability of the debrisoquine metabolic ratio to immunoperturbation by influenza and pneumococcus vaccines. Br. J. Clin. Pharmacol. 25: 141P (1988)

55.     Henthorn, T.K., Spina, E., Dumont, E., von Bahr, C.: In vitro inhibition of polymorphic human liver P-450 isozyme by narcotic analgesics. Anesthesiol. 70: 339 (1989)

56.     Steiner, E., Dumont, E., Spina, E., Dahlqvist, R.: Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther. 43: 577 (1988)

57.     Philip, P.A., James, C.A., Rogers, H.J.: The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers. Eur. J. Clin. Pharmacol. 36: 319 (1989)

58.     Inaba, T., Tyndale, R.E., Mahon, W.A.: Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br. J. Clin. Pharmacol. 22: 199 (1986)

59.     Gram, L.F., Debruyne, D., Caillard, V. Boulenger, J,P., Lacotte, J., Moulin, M., Zarifian, E.: Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br. J. Clin. Pharmacol. 27: 272 (1989)

60.     Ayesh, R., Idle, J.R., Ritchie, J.C., Crothers, M.J., Hetzel, M.R.: Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169 (1984)

61.     Idle, J.R., Mahgoub, A., Sloan, T.P., Smith, R.L., Nbanefo, CO., Bababunmi, E.A.: Some observations on the oxidation phenotype status of Nigeria patients presenting with cancer. Cancer Lett. 11: 331 (1981)

62.     Salminen, L., Lindberg, R., Toivari, H.R., Huupponen, R., Kaila, T., lisalo, E.: Prevalence of debrisoquine oxidation phenotypes in glaucoma patients. Int. Ophthalmol. 13: 91 (1989)

63.     Barbeau, A., Cloutier, T., Roy, M., Plasse, L, Paris, S., Poirier, J.: Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet 2: 1213 (1985)

64.     Baer, A.N., McAllister, C.B., Wilkinson, G.R., Woosley, R.L., Pincus, T.: Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum. 29: 843 (1986)

65.     Ritchie, J.C., Crothers, M.J., Idle, J.R. et al.: Evidence for an inherited metabolic susceptibility to endemic (Balkan) nephropathy. Proc. 5th Symp. Endemic (Balkan) Nephropathy, p. 23, University of Nis, 1983

66.     Boobis, A.R., Murray, S. Kahn, G.C., Robertz, G.M., Davies, D.S.: Substrate specificity of the form of cytochrome P450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol. Pharmacol. 23: 474 (1983)

67.     Otton, S.V., Inaba, T., Mahon, W.A., Kolow, W.: In vitro metabolism of sparteine by human liver, competitive inhibition by debrisoquine. Can. J. PhysioI. Pharmacol. 60: 102 (1982)

68.     Plessas, C.T., Plessas, S.T., Benakis, A.: Clinical pharmacokinetics of drug enantiomers. Epitheor. Klin. Farmakol. Farmakokinet. El. Ekd. 7: 86 (1989)

69.     Minder, E.I., Meier, P.J., Müller, H.K. et al.: Bufuralol metabolism, in human liver: A sensitive probe for the debrisoquine-type polymorphism of drug oxidation. Eur. J. Clin. Invest. 14: 184 (1984)

70.     Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U. et al.: Debrisoquine/sparteine-type polymorphism of drug oxidation: Purification and characterization of two functionally different human liver cytochrome P450 isozymes involved in impaired hydroxylation of the phenotype substrate bufuralol. J. Biol. Chem. 261: 11734 (1986)

71.     Gonzalez, F.J., Skoda, R.C., Kimura, S., Umeno, M., Zanger, U.M., Nebert, D.W., Gelboin, H.W., Hardwick, J.P., Meyer, U.A.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442 (1988)

72.     Gut, J., Gasser, R., Dayer, P., Kronbach, T., Catin, T.: Debrisoquine-type polymorphism of drug oxidation: Purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett. 173: 287 (1984)

73.     Distlerath, L.M., Reilly, P.E.B., Martin, M.V., Davies, G.C., Wilkinson, G.R.: Purification and characterization of the human liver cytochrome P450 involved in debrisoquine and phenacetin O-demethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260: 9057 (1985)

74.     Dayer, P., Gasser, R., Gut, J., Kronbach, T., Robertz, M.D.: Characterization of a common genetic defect of cytochrome P450 function (debrisoquine-sparteine type polymorphism) – increased Michaelis constant (Km) and loss of stereoselectivity of bufurarol 1’-hydroxylation in poor metabolizers. Biochem. Biophys. Res. Commun. 125: 374 (1984)

75.     Zanger, U.M., Hauri, H.P., Loeper, J., Homberg, J.C., Meyer, U.A.: Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc. Natl. Acad. Sci. USA 85: 8256 (1988)

76.     Zanger, U.M., Vilbois, F., Hardwick, J., Meyer, U.A.: Absence of hepatic.cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447 (1988)

77.     Gonzalez, F.J., Vilbois, F., Hardwick, J.P., McBride, O.W., Nebert, D.W., Gelboin, H.V., Meyer, U.A.: Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2: 174 (1988)

78.     Mura C., Broyart, J.P., Jacqz, E., Elion, J., Krishnamoorthy, R.: Ncol RFLP in the pseudogene (CYP2D8P) of the human debrisoquine 4-hydroxylase locus. Nucl. Acids Res. 19: 1162 (1991)

79.     Kimura, S., Umeno, M„ Skoda, R.C., Meyer, U.A., Gon-zalez, F.: The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45: 889 (1989)

80.     Meyer, U.A.: Molecular genetics and the future of pharmacogenetics. Pharmac. Ther. 46: 349 (1990)

81.     Skoda, R.C., Gonzalez, F.J., Demierre, A., Meyer, U.A.: Two mutant alleles of the human cytochrome P450db1- gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. USA 85: 5240 (1988)

82.     Yue, Q.Y., Bertilsson, L., Dahl-Puustinen, M.-L., Säwe, J., Sjöqvist, F., Johansson, I., Ingelman-Sundberg, M.: Dissociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet 2: 870 (1989)

83.     Caporaso, N., Pickle, L.: Debrisoquine phenotype and genotype in Chinese. Lancet ii: 1534 (1989)

84.     Mura, C., Broyard, J.P., Jacqz-Aigrain, E., Krishnamoorthy: Distinct phenotype and genotype of debrisoquine hydroxylation among Europeans and Chinese. Br. J. Clin. Pharmacol. accepted for publication (1991)

85.     Kupfer, A., Preisig, R.: Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man, Eur. J. Clin. Pharmacol. 26: 753 (1984)

86.     Kalow, W.: The genetic defect of mephenytoin hydroxylation. Xenobiotica 16: 379 (1986)

87.     Wedlund, P.J., Aslanian. W.S., Jacqz, E., McAllister, C.      B., Branch, R.A., Wilkinson, G.R.: Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J. Pharmacol Exp. Ther. 234: 662 (1985)

88.     Testa, B.: Substrate and product stereoselectivity in mono-oxygenase-mediated drug activation and inactivation. Biochem. Pharmacol 37: 85 (1988)

89.     Wedlund, P.J., Aslanian, W.S., McAllister, C.B. et al.: Deficiency of mephenytoin hydroxylation in a Caucasian population: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 36: 773 (1984)

90.     Bertilsson, L., Henthorn, T.K., Sanz, E., Tybring, G., Säwe, J., Villén, T.: Importance of genetic factors in the regulation of diazepam metabolism: relationship to S- mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin. Pharmacol Ther. 45: 348 (1989)

91.     Meier, U.T., Dayer, P., Male, P.-J., Kronbach, T., Meyer, U.A.: Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin. Pharmacol. Ther. 38: 488 (1985)

92.     Kiipfer, A., Desmond, P., Patwardhan, R. et al.: Mephenytoin hydroxylation deficiency: Kinetics after repeated doses. Clin. Pharmacol Ther. 35: 33 (1984)

93.     Gut, J., Meier, U.T., Catin, T., Meyer, U.A.: Mephenytoin-type polymorphism of drug oxidation: Purification and characterization of a human liver cytochrome P450 isozyme catalyzing microsomal mephenytoin hydroxylation. Biochim. Biophys. Acta 884: 435 (1986)

94.     Shimada, T., Misono, K.S., Guengerich, F.P.: Human liver microsomal cytochrome P450 mephenytoin-4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. J. Biol Chem. 261: 909 (1986)

95.     Relling, M.V., Aoyama, T., Gonzalez, F.J., Meyer, U.A.: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol Exp. Ther. 252: 442 (1990)

pharmakonpress[at]pharmakonpress[.]gr